Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Implementation of Ramadan "Fasting Algorithm for Singaporeans With Type 2 Diabetes" (FAST): A Prospective Randomized Controlled Intervention Study
Brief Summary: Background: Ramadan fasting is a religious observance carried out by Muslims all over the world. During Ramadan, Muslims abstain from eating, drinking, and smoking during daylight hours. Although Muslims who are ill, including patients with diabetes, are exempted from fasting, many devoted Muslim patients still insist on fasting despite being advised not to by their healthcare providers. Concerns have been raised over how the practice of fasting may affect the metabolic control of Muslim patients with diabetes. Furthermore, it has also been postulated that the act of fasting may increase the risk of hypoglycemia or glucose toxicity. Although practice algorithms and suggestions on the use of glycemic therapies during fasting have been discussed internationally. they are not generalizable as the observances of Ramadan, duration of fasting and the food ingested differ from one country to another.

Aims: This study aims to develop and implement a clinical practice dose-adjustment algorithm dedicated to the care of Singaporean patients with diabetes who fast during Ramadan.

Hypothesis: The use of clinical practice dose-adjustment algorithm can improve both clinical and humanistic outcomes of patients with type 2 diabetes who wish to fast during Ramadan.

Methods: This is a prospective, randomized, interventional study involving patients with type 2 diabetes who wish to fast for at least 10 days during Ramadan. Eligible patient attending a primary care institution or an outpatient specialist clinic of a tertiary institution will be approached to participate in the study. Consented patients will be randomized to either intervention arm or control arm. Patients in the control arm will receive usual care while patients in the intervention arm will be given additional education session on Ramadan fasting related diabetic management advice and an algorithm that was developed by the study team members based on international guidelines, to guide them on self-management during Ramadan. The primary outcomes will be change in HbA1c. Secondary outcomes include change in fasting blood glucose, post prandial blood glucose, medication adherence and humanistic outcomes. The safety outcomes include self reported incidence of major and minor hypoglycemia as well as hyperglycemia during Ramadan month. All outcomes will be measured at baseline, during Ramadan and at 3 month post Ramadan.

Significance: The validation of the algorithm through this study will ensure effective and safe fasting of patients with type 2 diabetes during Ramadan.


Options:
A: Arm Label: Intervention; Type: OTHER; Interventions: Other: FAST | Arm Label: Control; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: FAST; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Control
B: Arm Label: Vildagliptin + placebo to Gliclazide; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin, Drug: Placebo to Gliclazide | Arm Label: Gliclazide + placebo to Vildagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gliclazide, Drug: Metformin, Drug: Placebo to Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Gliclazide; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin, Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Gliclazide; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Vildagliptin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin
C: Arm Label: Low-dosage therapy; Type: EXPERIMENTAL; Interventions: Drug: Metformin and Glimepiride (Low Dosage), Drug: Metformin and Vildagliptin (Low Dosage), Drug: Metformin and Insulin Glargine U100 (Low Dosage), Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage) | Arm Label: Regular-dosage therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin and Glimepiride (Regular Dosage), Drug: Metformin and Vildagliptin (Regular Dosage), Drug: Metformin and Insulin Glargine U100 (Regular Dosage), Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage) | Intervention Type: DRUG; Name: Metformin and Glimepiride (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Vildagliptin (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Insulin Glargine U100 (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Glimepiride (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin and Vildagliptin (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin and Insulin Glargine U100 (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy
D: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin, Drug: Metformin | Arm Label: Sulfonylurea Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): Sulfonylurea Therapy | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Sitagliptin, Sulfonylurea Therapy

Answer: A